Upstream Bio Announces Phase 3 Plans For Verekitug At 400 mg Every 12 Weeks In Severe Asthma And CRSwNP, With About 1,500 Patients Across Two Placebo-Controlled Trials; On Track To Initiate Q1 2027
Share
Why It Matters
Upstream Bio is testing a new asthma medicine called Verekitug with a large group of patients to see if it really works. This is an important step forward for the company, and you can watch to see if their tests go well over the next couple of years.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.